Today, a Director at Soligenix (SNGX), Jerome Zeldis, bought shares of SNGX for $7,200.
This recent transaction increases Jerome Zeldis’ holding in the company by 144.57% to a total of $13.36K. This is Zeldis’ first transaction since reporting a Buy transaction on ALQA back in March 2017
See today’s analyst top recommended stocks >>
Currently, Soligenix has an average volume of 476.6K.
Starting in May 2018, SNGX received 10 Buy ratings in a row.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense.
